# Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

> **NCT05428007** · PHASE2 · RECRUITING · sponsor: **NYU Langone Health** · enrollment: 105 (estimated)

## Conditions studied

- Melanoma
- Unresectable Melanoma

## Interventions

- **DRUG:** Sarilumab
- **DRUG:** Ipilimumab Injection
- **DRUG:** Nivolumab/Relatlimab

## Key facts

- **NCT ID:** NCT05428007
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-02
- **Primary completion:** 2026-08
- **Final completion:** 2028-02
- **Target enrollment:** 105 (ESTIMATED)
- **Last updated:** 2026-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05428007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05428007, "Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05428007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*